Cervical cancer is the most preventable forms of cancer, and yet it is the most common cancer affecting women in Thailand today. With adequate screening regimens and use of the right technology, early signs and risk factors can be detected and managed.

WMED’s Women Healthcare business unit offer world leading technologies for comprehensive cervical cancer screening and diagnosis, promoting a healthier future for Thailand.

In additional to cervical cancer, WMED’s Women Healthcare business unit is committed to several other aspects of female healthcare. Our range of products which is constantly expanding, now includes Maternal-Fetal medicine. This comprises of Down’s syndrome and genetic screening test, pregnancy monitoring and cervical dilators.

Cervical cancer screening

ThinPrep PAP Test

ThinPrep PAP Test was introduced in 2003, is the most trusted and comprehensive Pap test available today.

The ThinPrep Pap Test is one of the first Pap tests to utilize liquid-based cytology. It’s introductions represents the most significant advancement in cervical cancer screening technology.

The ThinPrep Pap Test was lunched in 1996 and quickly adopted as the most widely used Pap test in the USA. Since then, invasive cervical cancers in the country have dropped by nearly 30%.

Benefits of the ThinPrep Pap Test include; increased screening accuracy and superior patient comfort; multiple tests can be performed using one sample specimen, which limits the need for further samples to be collected. The ThinPrep Pap Test Provides screening for human papillomavirus (HPV) making it an invaluable step in establishing all-round awareness of patient’s state of health.

The effectiveness of the ThinPrep Pap Test can be borrowed by using the ThinPrep Imaging System with Dual Review. Combining the benefits of automated hardware screening and manual review by cytotechnologists, the ThinPrep Imaging System with Dual Review increases the probability of detecting abnormalities and reduces false negative test results

For further information

Product Specification
Cervical cancer screening
HPV molecular testing : 14 types high risk

Aptima HPV HR

The APT HPV ASSEY was introduced in 2011

To identify high-risk HPV infections by targeting E6/E7 mRNA. Studies show that targeting E6/E7 mRNA identifies the presence and activity of a high-risk HPV infection. The APT HPV ASSEY represents the next generation in cervical screening – allowing clinicians to deliver maximum benefit to patients, while minimizing potential harm.

The APT HPV ASSEY identifies patients at greatest risk of developing cervical cancer, delivering the same excellent sensitivity to minimize false negative results. The APT HPV ASSEY demonstrates the same excellent sensitivity as DNA-based HPV tests in numerous clinical studies involving over 50,000 women worldwide.

APT HPV ASSEY tests exhibit the same excellent sensitivity as DNA based tests while offering increased specificity. It is FDA-approved for use with the ThinPrep Pap Test aligned with cervical cancer screening guidelines.

For further information

Product Specification
Cervical cancer screening
HPV molecular testing : 14 types high risk

Aptima Combo2 For Ct/Ng Assay

APTIMA COMBO2 was introduced in 2014

Chlamydia and gonorrhea are the most commonly reported notifiable sexually transmitted bacterial infections. In the United States there are over 3 million new cases annually and worldwide. The World Health Organization estimates the annual incidence of chlamydia to be 105.7 million and 106.1 million for gonorrhea.

The Centers for Disease Control and Prevention (CDC) estimates that only 38% of sexually active young women are screened annually for chlamydia in the United States and that up to 75% of CT infected women are asymptomatic contributing to as many as 30% of CT infections progressing to pelvic inflammatory disease (PID) which has been shown to cause permanent damage to a woman’s reproductive system including infertility, chronic pelvic pain and ectopic pregnancy.

For further information

Product Specification
Cervical cancer screening
HPV molecular testing : 14 types high risk

CERVISTA® HPV HR

CERVISTA HPV HR was introduced in 2009

To provide clinicians and laboratories with a human papillomavirus (HPV) testing in which they can have the utmost confidence.

Cervista HPV HR tests for all 14 oncogenic strains of HPV. The specialized internal control safeguards against false negatives due to insufficient cellularity, and there is no cross-reactivity with common low-risk HPV types that could otherwise cause false positive results.

Cervista HPV HR is the ideal next stage after an ASC-US Pap test result. The cytology results from Cervista HPV HR test indicate whether referral to colposcopy is necessary or not. Due to the superlative accuracy of Cervista HPV HR, clinicians, laboratories and patients can rest assured that the course of patient care will be defined strictly by their needs, not misleading results.

Product Specification
Preterm screening
Biomarker Testing of Fetal Fibronectin

Fetal Fibronectin Test

FETAL FIBRONECTIN (FFN) TEST is a powerful tool for predicting preterm birth, introduced in 2008.

12 out of every 100 children born in Thailand are delivered preterm. Preterm birth is the most common cause of health problems in newborns today. Certain physical symptoms typically indicate that a mother is at risk of delivering prematurely. However, even if such if such symptoms occurred it does not mean that mother is at risk of delivering prematurely, conversely , preterm births can also occur in the absence of symptoms.

The fFN test presents a more reliable method of determining the likelihood of preterm birth. Administered similarly to a Pap Test, the FFN test is a safe and non-invasive method of measuring fFN levels in vaginal secretions. Usually, fFN can only be detected at the beginning of pregnancy and towards full term. Detectable levels of fFN from weeks 22 to 35 of pregnancy are a strong indicator that the patient is at high risk of delivering their baby preterm.

The fFN is valuable for its role in identifying patients who are not at risk for preterm birth. Mothers whose symptoms would otherwise be addressed with medication or lying-in can avoid disruption to their daily lives.

For further information

Product Specification
Screening for the fetus

Detect common chromosome abnormalities of fetus

“What are Chromosomes ?”
Chromosomes are structures inside cells. They carry heredity information that guide our bodies how to grow and develop. Most people have 23 pairs of Chromosome. The first 22 pairs are called Autosome, and the 23rd pair is Chromosome related to gender-the X and Y Chromosome. Females usually have two XX while males have one X and one Y.

Aneuploidy is a condition where the number of Chromosomes are not exactly 23 pairs. An extra or missing Chromosome is a common cause of genetic disorders including human birth defects. The most common Chromosome Aneuploidies are trisomy 21 (Down Syndrome), trisomy 18 (Edwards Syndrome), and trisomy 13 (Patau Syndrome).

NIPS PRENATAL TEST
Cell-free fetal DNA (cffDNA) is fetal DNA circulating freely in the maternal blood stream during pregnancy. It can be sampled by venipuncture on the mother. The test used a technology called “Next Generation Sequencing (NGS)” to count the number of copies of these Chromosome, and then uses a calculation method to determine if there are chromosomal aneuploidies. By using this powerful biotechnology, we provide 99% accuracy especially Trisomy 21, Trisomy 18 and Trisomy 113 from a single blood drawn (one tube) early as 10 weeks estimated gestational age and report within 8 business days.